Oral anticoagulants for primary and secondary prevention of venous thromboembolism


Authors: Peter Gavorník;  Andrej Dukát;  Ľudovít Gašpar;  Gabriela Gubo;  Naďa Hučková
Authors‘ workplace: Angiologická sekcia Slovenskej lekárskej komory, Bratislava, Slovenská republika
Published in: Vnitř Lék 2016; 62(9): 746-750
Category: Guidelines

Overview

Until recently, vitamin K antagonists (VKA; predominantly warfarin) were the only oral anticoagulants for primary and secondary prevention of venous thromboembolism. Prevention and therapy with novel, direct, non-VKA oral anticoagulant agents (NOACs; DOACs: dabigatran, rivaroxaban, apixaban, edoxaban), have recently become available as an alternative to VKA. NOACs have been shown to be non-inferior or superior to VKA in clinical trials. Available results suggest that real world safety of NOACs is mostly consistent with results observed in clinical trials. The most effective method is triple simultaneous prevention of venous thromboembolism (pharmaco kinezio mechano phlebothromboemboloprophylaxis).

Key words:
oral anticoagulants – NOAC/DOAC – thromboprophylaxis – venous thromboembolism – VKA


Sources

1. Gavorník P. Kombinovaná flebotromboemboloprofylaxia (prevencia vénovej tromboembólie) v lekárskej klinickej praxi. Medikom/MediNews 2012; 2(1): 18–21.

2. Gavorník P, Mátyás K. Flebotromboemboloprofylaxia vénovej tromboembólie (VTE) – 3. verzia odporúčaní AS SLK, 2014. Medikom/MediNews 2014; 4(4): 12–14.

3. Gavorník P, Gašpar Ľ, Dukát A. Kombinovaná kinezio-flebotromboemboloprofylaxia, mechano-flebotromboemboloprofylaxia a farmako-flebotromboemboloporofylaxia vénovej tromboembólie v internej medicíne. Vnitř Lék 2012; 58(11): 851–855.

4. Kearon C, Akl EA, Ornelas J et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest 2016; 149(2): 315–352. Dostupné z DOI: <http://dx.doi.org/10.1016/j.chest.2015.11.026>.

5. Nicolaides AN, Fareed J, Kakkar AK et al. Prevention and treatment of venous thromboembolism. International Consensus Statement (Guidelines according to scientific evidence). Int Angiol 2013; 32(2): 111–260.

6. Nicolaides AN, Kakkos S, Eklof B et al. Management of chronic venous disorders of the lower limbs. Guidelines according to scientific evidence. Int Angiol 2014; 33(2): 87–208.

7. Roussin A. Effective management of acute deep vein thrombosis: direct oral anticoagulants. Int Angiol 2015; 34(1): 16–29.

8. Lee BB, Nicolaides AN, Myers K et al. Venous hemodynamic changes in lower limb venous disease: the UIP consensus according to scientific evidence. Int Angiol 2016; 35(3): 236–352.

9. Paikin JS, Hirsh J, Chan NC et al. Timing the First Postoperative Dose of Anticoagulants: Lessons Learned From Clinical Trials. Chest 2015; 148(3): 587–595. Dostupné z DOI: <http://dx.doi.org/10.1378/chest.14–2710>.

10. Gavorník P. Najčastejšie choroby vénového cievneho systému. Univerzita Komenského: Bratislava 2014. ISBN 978–80–223–3453–2.

11. Gary T. Cancer related venous thromboembolism – prophylaxis and therapy. Vasa 2014; 43(4): 245–251. Dostupné z DOI: <http://10.1024/0301–1526/a000359>.

12. Partsch H. Compression therapy for deep vein thrombosis. Vasa 2014; 43(5): 305–307. Dostupné z DOI: <http://dx.doi.org/10.1024/0301–1526/a000368>.

13. Turpie AG. Extended duration of thromboprophylaxis in acutely ill medical patients: optimizing therapy? J Thromb Haemost 2007; 5(1): 5–11.

14. Cohen AT, Alikhan R, Arcelus J et al. Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost 2005; 94(4): 750–759.

15. Van Es N, Bleker SM, Wilts IT et al. Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: Focus on Drug Therapy. Drugs 2016; 76(3): 331–341. Dostupné z DOI: <http://dx.doi.org/10.1007/s40265–015–0526–3>.

16. Gavorník P, Dukát A, Gašpar Ľ et al. Súčasnosť a budúcnosť v manažmente vénových vaskulárnych chorôb. Vnitř Lék 2015; 61(2): 151–156.

17. Hirschl M, Kundi M. New oral anticoagulants in the treatment of acute venous thromboembolism – a systematic review with indirect comparisons. Vasa 2014; 43(5): 353–364. Dostupné z DOI: <http://dx.doi.org/10.1024/0301–1526/a000373>. Erratum in Vasa. 2014; 43(6): 477.

18. Gavorník P. Angiológia 1 pre všeobecných praktických lekárov. Flebológia. Dr. Josef Raabe: Bratislava 2013. ISBN 978–80–8140–083–4.

19. Dobesh PP, Fanikos J. New Oral Anticoagulants for the Treatment of Venous Thromboembolism: Understanding Differences and Similarities. Drugs 2014; 74(17): 2015–2032. Dostupné z DOI: <http://dx.doi.org/10.1007/s40265–014–0301-x>.

20. Mega JL, Simon T. Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments. Lancet 2015; 386(9990): 281–291. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(15)60243–4>.

21. Remková A et al. Žilová trombóza a pľúcna embólia.: Samedi: Bratislava 2013. ISBN 978–80–970825–2-9

22. Barillari G, Londero AP, Brenner B et al. Recurrence of venous thromboembolism in patients with recent gestational deep vein thrombosis or pulmonary embolism: Findings from the RIETE Registry. Eur J Intern Med 2016; 32: 53–59. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ejim.2016.02.013>.

23. Grüne S, Orlik J, Von Korn H et al. Clinical signs in the diagnosis of deep vein thrombosis. Int Angiol 2011; 30(1): 64–70.

24. Palareti G, Antonucci E, Lip GY et al. [START-register participants]. The SAMe-TT2R2 score predicts the quality of anticoagulation control in patients with acute VTE. A real-life inception cohort study. Thromb Haemost 2016; 115(6): 1101–1108. Dostupné z DOI: <http://dx.doi.org/10.1160/TH15–10–0830>.

25. Hull RD, Schellong SM, Tapson VF et al. [EXCLAIM (Extended Prophylaxis for Venous ThromboEmbolism in Acutely Ill Medical Patients with Prolonged Immobilization) study]. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med 2010; 153(1): 8–18. Dostupné z DOI: <http://dx.doi.org/10.7326/0003–4819–153–1-201007060–00004>.

26. Gavorník P. Cestovná trombóza a varixy. Interní Med 2008; 10(5): 219–223.

27. Gavorník P, Dukát A, Gašpar Ľ. Manažment povrchovej tromboflebitídy. Odporúčania Angiologickej sekcie Slovenskej lekárskej komory (2013). Vnitř Lék 2013; 59(11): 1009–1016.

28. Konstantinides SV, Torbicki A, Agnelli G et al. [The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC)]. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014; 35(43): 3033–3069, 3069a-3069k. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehu283>.

29. Vaughan-Shaw PG, Cannon C. Venous thromboembolism prevention in medical patients: a framework for improving practice. Phlebology 2011; 26(2): 62–68. Dostupné z DOI: <http://dx.doi.org/10.1258/phleb.2010.010003>.

30. Knepper J, Ramacciotti E, Wakefield TW. Novel anticoagulants: a discussion of clinical use in the treatment and prevention of venous thromboembolism. Phlebology 2011; 26(1): 3–7. Dostupné z DOI: <http://dx.doi.org/10.1258/phleb.2010.010023>.

31. Becattini C, Lignani A, Masotti L et al. D-Dimer for risk stratification in patients with acute pulmonary embolism. J Thromb Thromb 2012; 33(1): 48–57. Dostupné z DOI: <http://dx.doi.org/10.1007/s11239–011–0648–8>.

32. Dasari TW, Pappy R, Hennebry TA. Pharmacomechanical Thrombolysis of Acute and Chronic Symptomatic Deep Vein Thrombosis: A Systematic Review of Literature. Angiology 2012; 63(2): 138–145. Dostupné z DOI: <http://dx.doi.org/10.1177/0003319711410050>.

33. Konstantidines S, Torbicki A. Management of venous thrombo-embolism: an update. Eur Heart J 2014; 35(41): 2855–2863. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehu243>.

34. Moreno AIF, Navarro MJG, Sanches JO et al. A risk score for prediction of recurrence in patients with unprovoked venous thromboembolism (DAMOVES). Eur J Intern Med 2016; 29: 59–64. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ejim.2015.12.010>.

35. Harenberg J, Kalodiki E, Walenga JM. [Working Group of the IUA Scientific Committee]. Ensuring safety of biosimilar low-molecular-weight heparins: a consensus statement of the International Union of Angiology. Int Angiol 2012; 31(2): 101–104.

36. Pollack CV, Reilly PA, Eikelboom J et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015; 373(6): 511–520. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1502000>.

37. Cohen AL, Lim CS, Davies AH. Is there a role yet for new direct oral anticoagulants in cancer patients? Phlebology 2016; 31(3): 157–159. Dostupné z DOI: <http://dx.doi.org/10.1177/0268355515604255>.

38. Rennenberg RJ. Oral anticoagulants, effect on thrombus resolution and post-thrombotic syndrome. Phlebology 2016; 31(1 Suppl): S24-S27. Dostupné z DOI: <http://dx.doi.org/10.1177/0268355516632101>.

39. Cohen AT, Harrington RA, Goldhaber SZ et al. Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. N Engl J Med 2016; 375(6): 534–544. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1601747>.

40. Siegal DM, Cumutte JT, Connolly SJ et al. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl J Med 2015; 373(25): 2413–2424. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1510991>.

41. Piazza G, Mani V, Goldhaber et al. for edoxaban Thrombus Reduction Imaging Study (eTRIS) investigators. Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility study. Vasc Med 2016; 21 (4): 361–368.

Labels
Diabetology Endocrinology Internal medicine
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account